	US 12,480,130 B2
	Aptamer against irinotecan
Katarzyna Bialas, York (GB); Christine Reinemann, York (GB); Edward Barnes, York (GB); David Bunka, York (GB); and Arron Tolley, York (GB)
Assigned to APTAMER DIAGNOSTICS LIMITED, North Yorkshire (GB)
Appl. No. 17/415,998
Filed by APTAMER DIAGNOSTICS LIMITED, York (GB)
PCT Filed Nov. 27, 2019, PCT No. PCT/GB2019/053355 § 371(c)(1), (2) Date Jun. 18, 2021, PCT Pub. No. WO2020/128421, PCT Pub. Date Jun. 25, 2020.
Claims priority of application No. 1820631 (GB), filed on Dec. 18, 2018.
Prior Publication US 2022/0049258 A1, Feb. 17, 2022
Int. Cl. C12N 15/115 (2010.01); A61K 31/4745 (2006.01); G01N 33/94 (2006.01)

CPC C12N 15/115 (2013.01) [A61K 31/4745 (2013.01); G01N 33/94 (2013.01); C12N 2310/16 (2013.01); C12N 2320/10 (2013.01); G01N 2800/52 (2013.01)]

21 Claims

1. An aptamer capable of specifically binding to Irinotecan, wherein the aptamer comprises a nucleic acid sequence comprising SEQ ID NO: 10.